Investment Rating - The investment rating for the company is "Outperform the Market" [6][20][25] Core Views - The company is expected to achieve revenue of 1.56 billion in 2024, representing a year-over-year increase of 13.4%, with a net profit of 161 million, up 14.07% year-over-year [1][8] - The adult basic oral care segment remains the primary revenue source, generating 1.407 billion in 2024, accounting for 90.22% of total revenue [2][9] - The company is focusing on product upgrades and channel expansion, particularly through online sales, which have shown significant growth [1][4][20] Revenue and Profitability - In Q4 2024, the company achieved a revenue growth of 39.12% and a net profit growth of 28.58% [1][8] - The gross margin for 2024 is projected to be 49.37%, an increase of 5.26 percentage points year-over-year [13][18] - The company plans to distribute a cash dividend of 7.5 per 10 shares (tax included) [1][8] Segment Performance - The adult basic oral care segment's revenue grew by 14.48% year-over-year, while the children's segment saw a decline of 1.90% [2][9] - The e-commerce channel is experiencing robust growth, with a revenue increase of 51.99% in 2024, raising its contribution to 30.81% of total revenue [2][9] Future Outlook - The company is expected to maintain healthy growth in Q1 2025, with projected revenue of 430 million, a year-over-year increase of 19.36% [3][10] - The net profit for 2025 is forecasted to reach 224 million, reflecting a growth rate of 39.1% [5][20] - The company aims to enhance its market position through diversified expansion and brand strengthening via social media channels [4][20]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][14]. Core Insights - The company reported a revenue of 1.56 billion yuan for 2024, representing a year-over-year growth of 13.4%, with a net profit of 161 million yuan, up 14.1% year-over-year. The fourth quarter of 2024 saw a significant revenue increase of 39% year-over-year [4][5]. - The company's online sales are driven by a major product, with e-commerce revenue growing by 52% year-over-year, indicating strong growth potential for 2025 [5]. - The gross profit margin for 2024 was 49.4%, an increase of 5.3 percentage points year-over-year, reflecting improved profitability [6]. - The company is expected to continue expanding its market share in oral care and beauty, with projected net profits of 200 million yuan, 252 million yuan, and 317 million yuan for 2025, 2026, and 2027 respectively [7][10]. Financial Summary - The latest closing price of the company's stock is 44.68 yuan, with a total market capitalization of 7.7 billion yuan [3]. - The company’s earnings per share (EPS) for 2024 is projected at 0.94 yuan, with a price-to-earnings (P/E) ratio of 47.73 [10][13]. - The company’s revenue is expected to grow to 1.89 billion yuan in 2025, with a growth rate of 21.3% [10][11].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][14]. Core Insights - The company reported a revenue of 1.56 billion yuan for 2024, representing a year-over-year growth of 13.4%, with a net profit of 161 million yuan, up 14.1% year-over-year [4]. - The fourth quarter of 2024 saw a significant revenue increase of 39% year-over-year, reaching 507 million yuan, with a net profit of 43 million yuan, up 28.6% year-over-year [4]. - The first quarter of 2025 continued this trend with a revenue of 430 million yuan, a 19.4% increase year-over-year, and a net profit of 43 million yuan, up 15.6% year-over-year [4]. Revenue Breakdown - In 2024, the company's revenue from different channels was as follows: distribution model 1.03 billion yuan (+3.7% YoY), direct supply model 40 million yuan (-24.0% YoY), and e-commerce model 480 million yuan (+52.0% YoY) [5]. - The revenue from various product categories in 2024 included: adult toothpaste 1.25 billion yuan (+16.1% YoY), adult toothbrush 160 million yuan (+3.3% YoY), children's toothpaste 70 million yuan (-0.5% YoY), children's toothbrush 30 million yuan (-5.1% YoY), electric toothbrush 10 million yuan (-14.3% YoY), and oral medical and beauty care products 40 million yuan (+35.5% YoY) [5]. Profitability Analysis - The company's gross margin for 2024 was 49.4%, an increase of 5.3 percentage points year-over-year, while the net profit margin was 10.3%, showing a slight improvement [6]. - In the first quarter of 2025, the gross margin rose to 55.5%, a year-over-year increase of 7.1 percentage points, while the net profit margin slightly decreased to 10.0% due to fluctuations in fair value changes [6]. Financial Forecast and Investment Recommendations - The company is expected to see steady growth in its core oral care market, with projected net profits of 200 million yuan, 250 million yuan, and 320 million yuan for 2025, 2026, and 2027 respectively, corresponding to price-to-earnings ratios of 39x, 31x, and 24x [7]. - The report highlights the company's strong cash flow and high dividend payout ratio, which are expected to enhance its valuation premium [7]. Financial Metrics - The projected revenue for the company is expected to grow from 1.56 billion yuan in 2024 to 2.78 billion yuan in 2027, with a compound annual growth rate of approximately 20.87% [10]. - The earnings per share (EPS) is forecasted to increase from 0.94 yuan in 2024 to 1.84 yuan in 2027 [10].

Investment Rating - The investment rating for the company is "Add" (maintained) [6] Core Views - The company achieved a revenue of 1.56 billion yuan in 2024, representing a year-on-year increase of 13.4%, and a net profit of 160 million yuan, up 14.1% year-on-year [1] - The adult toothpaste segment showed excellent growth, with revenue increasing by 16.1%, while the e-commerce channel remains the core driver of the company's growth [2] - The optimization of product structure has significantly boosted the gross margin, which reached 49.37% in 2024, up 5.3 percentage points year-on-year [3] Financial Performance - In 2024, the company reported a net cash flow from operating activities of 181 million yuan, a year-on-year increase of 20.1% [4] - The company's gross margin for adult toothpaste was 50.47%, reflecting a 5.5 percentage point increase year-on-year [3] - The company’s net profit margin for 2024 was 10.33%, a slight increase of 0.06 percentage points year-on-year [3] Market Position - The company has maintained a steady increase in market share, ranking third in the offline retail channel for toothpaste products, and second among domestic brands [5] - The "Cold Acid Spirit" brand has seen its market share in the sensitive toothpaste segment increase from 61.74% in 2022 to 64.72% in 2024 [5] Earnings Forecast - The company is expected to achieve revenues of 1.87 billion yuan, 2.27 billion yuan, and 2.80 billion yuan in 2025, 2026, and 2027, respectively, with year-on-year growth rates of 19.65%, 21.73%, and 23.21% [10] - The forecasted net profit for 2025 is 196 million yuan, representing a year-on-year growth of 21.75% [10]

Core Viewpoint - The company reported a revenue of 1.56 billion yuan for 2024, representing a year-over-year increase of 13.4%, and a net profit attributable to shareholders of 160 million yuan, up 14.1% year-over-year, meeting expectations [1] Financial Performance - For Q4 2024, the company achieved a revenue of 510 million yuan, a year-over-year increase of 39.1%, with a net profit of 40 million yuan, up 28.6% year-over-year [1] - In Q1 2025, the company reported a revenue of 430 million yuan, a year-over-year increase of 19.4%, with a net profit of 40 million yuan, up 15.6% year-over-year [1] Product Category Performance - Adult toothpaste revenue reached 1.25 billion yuan, a year-over-year increase of 16.1%, with H1 and H2 growth rates of 7.0% and 24.4% respectively [2] - Adult toothbrush revenue was 160 million yuan, a year-over-year increase of 3.3%, with H1 and H2 growth rates of 0.6% and 6.1% respectively [2] - Oral medical and beauty care products generated 40 million yuan in revenue, a year-over-year increase of 35.5%, with H1 and H2 growth rates of -10.5% and +87.6% respectively [2] - Children's toothpaste and toothbrush revenues were relatively weak, at 70 million yuan and 30 million yuan respectively, with year-over-year changes of -0.5% and -5.1% [2] Sales Model Analysis - The distribution model generated 1.03 billion yuan in revenue, a year-over-year increase of 3.7%, accounting for 66% of total revenue [3] - The e-commerce model saw revenue of 480 million yuan, a year-over-year increase of 52.0%, accounting for 31% of total revenue [3] - The direct supply model reported revenue of 40 million yuan, a year-over-year decrease of 24.0% [3] Margin and Cost Analysis - The gross margin was 50.5%, an increase of 5.5 percentage points year-over-year, with H1 and H2 margins at 48.1% and 52.3% respectively [2] - The company’s gross margin, period expense ratio, and net profit margin for 2024 were 49.4%, 39.1%, and 10.3% respectively, showing year-over-year increases [3] Investment Outlook - The company is expected to continue benefiting from high-priced differentiated products driving e-commerce growth, which may enhance the willingness of offline distributors to stock higher-margin products [4] - Projected net profits for 2025-2027 are 210 million yuan, 240 million yuan, and 260 million yuan respectively, with year-over-year growth rates of 27.2%, 16.5%, and 10.5% [4]

重庆登康口腔护理用品股份有限公司 关于举办2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆登康口腔护理用品股份有限公司（以下简称"公司"）已于2025年4月22日在 巨潮资讯网上披露了《2024年年度报告》全文及其摘要。为便于广大投资者更加全面 深入地了解公司经营业绩、发展战略等情况，公司定于2025年4月25日（星期五） 15:00～16:00在"价值在线"（www.ir-online.cn）举办2024年度网上业绩说明会，与投 资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 证券代码：001328 证券简称：登康口腔 公告编号：2025-022 注：如遇特殊情况，参会人员可能进行调整。 三、投资者参与方式 投 资 者 可 于 2025 年 4 月 25 日 （ 星 期 五 ） 15:00 ～ 16:00 通过网址 https://eseb.cn/1nFZWtTueEU或使用微信扫描下方小程序码参与互动交流，公司将在信 息披露允许范围内就投资者普遍关注的问题进行回答。 为提升交流的针对 ...

Investment Rating - The report upgrades the company to a "Buy" rating, reflecting a positive outlook for the next 6-12 months with expected price increases [3]. Core Insights - The company reported a revenue of 1.56 billion RMB for 2024, representing a year-on-year growth of 13.4%, and a net profit of 161 million RMB, up 14.07% year-on-year [2]. - The growth is driven by the successful launch of high-demand products, particularly in the sensitive teeth segment, and effective marketing strategies leveraging platforms like Douyin [3][2]. - The company is positioned as a leader in the sensitive oral care niche, with a significant market share in various product categories [3]. Performance Analysis - For 2024, the revenue breakdown by product includes adult toothpaste (1.247 billion RMB), adult toothbrushes (161 million RMB), children's toothpaste (72 million RMB), and electric toothbrushes (10 million RMB), with notable growth in sensitive care products [2]. - The revenue from different channels shows a significant increase in e-commerce sales by 51.99%, while direct supply and distribution channels experienced declines [2]. - The gross margin for 2024 is reported at 49.37%, an increase of 5.27 percentage points year-on-year, driven by the introduction of high-end products [3]. Financial Projections - The company is projected to achieve net profits of 200 million RMB, 258 million RMB, and 332 million RMB for the years 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 38.48, 29.78, and 23.17 [3][7]. - The expected revenue growth rates for the upcoming years are 27.91% for 2025, 20.88% for 2026, and 18.20% for 2027, indicating a strong growth trajectory [7]. Market Position - The company ranks third in retail sales market share for toothpaste in offline channels, and its children's toothpaste and toothbrushes are positioned third and first in their respective categories [2]. - The report highlights the company's ability to leverage social media marketing to enhance brand visibility and drive sales growth [3].

Investment Rating - The report upgrades the company to a "Buy" rating, indicating an expected price increase of over 15% in the next 6-12 months [3][11]. Core Insights - The company reported a revenue of 1.56 billion RMB for 2024, a year-on-year increase of 13.4%, and a net profit of 161 million RMB, up 14.07% year-on-year, with a net profit margin of 10.33% [2]. - The growth is driven by the popularity of Douyin and the rapid expansion of key products, enhancing brand strength [2][3]. - The company is positioned as a leader in the sensitive oral care segment, leveraging product upgrades to increase customer spending and attract new customers [3]. Performance Analysis - For 2024, revenue from adult toothpaste, adult toothbrushes, children's toothpaste, children's toothbrushes, electric toothbrushes, and oral medical and beauty care products is reported as 1.247 billion, 161 million, 72 million, 30 million, 10 million, and 38 million RMB respectively, with growth rates of 16.09%, 3.30%, -0.48%, -5.09%, -14.33%, and +35.45% [2]. - The company achieved a gross margin of 49.37% in 2024, an increase of 5.27 percentage points year-on-year, driven by high-end product series [3]. - The sales expense ratio for 2024 is 31.96%, up 3.88 percentage points, primarily due to marketing efforts on platforms like Douyin [3]. Revenue and Profit Forecast - The company is expected to achieve net profits of 200 million, 258 million, and 332 million RMB for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 38.48, 29.78, and 23.17 [3][7]. - The projected revenue growth rates for the next few years are 27.91% for 2025, 20.88% for 2026, and 18.20% for 2027 [7]. Market Position - The company ranks third in retail market share for toothpaste products in offline sales channels, and its children's toothpaste and toothbrushes rank third and first in their respective categories [2]. - The company holds a 64.72% market share in the sensitive segment of offline retail [2]. Channel Performance - Revenue from distribution, direct supply, and e-commerce for 2024 is reported as 1.032 billion, 41 million, and 481 million RMB respectively, with year-on-year growth rates of 3.69%, -24.01%, and +51.99% [2]. - The introduction of the medical research 7-day repair series is expected to continue driving the trend of popular products across various channels [2].

Core Viewpoint - The company, Chongqing Dengkang Oral Care Products Co., Ltd., has released its 2024 annual report, highlighting its financial performance, operational strategies, and future development plans. Company Overview - The company is transitioning from a traditional manufacturing entity to a comprehensive solution provider, driven by innovations in biotechnology, artificial intelligence, cloud computing, big data, 5G, and the Internet of Things [4][12]. - The company emphasizes a dual-driven growth model combining organic growth and external expansion [4]. Financial Performance - For the year 2024, the company achieved a consolidated revenue of CNY 1,560,070,850.25, representing a year-on-year increase of 13.40% [34]. - The net profit attributable to shareholders was CNY 161,179,433.51, reflecting a growth of 14.07% compared to the previous year [34]. Profit Distribution - The board approved a profit distribution plan, proposing a cash dividend of CNY 7.50 per 10 shares, totaling CNY 129,130,350.00, with no bonus shares issued [24][25]. Research and Development - The company adopts a "marketing + R&D" dual-driven development strategy, focusing on market needs and maintaining a technology innovation system [5][7]. - It has established a collaborative innovation ecosystem with various universities and research institutions to enhance its technological capabilities [8]. Sales and Marketing Strategy - The company has developed a marketing network that includes distribution, direct supply, and e-commerce models, effectively reaching consumers across various channels [11][12]. - The strategy aims to enhance brand awareness and market penetration, supporting the growth of the oral health industry [12]. Governance and Compliance - The board of directors has ensured compliance with relevant laws and regulations, maintaining transparency and accountability in its operations [19][21]. - The company has also approved the continuation of its auditing firm, Xinyong Zhonghe, for the 2025 fiscal year [30].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001328证券简称：登康口腔公告编号：2025-012 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）和深圳证券交易所印发的《深圳证券交易所上市公司自 律监管指引第1号——主板上市公司规范运作（2023年12月修订）》（深证上〔2023〕1145号）的规 定，将本公司募集资金2024年度存放与使用情况专项说明如下： 一、 募集资金基本情况 （一） 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意重庆登康口腔护理用品股份有限公司首次公开发行股票注册的 批复》（证监许可〔2023〕585号），本公司由主承销商中信建投证券股份有限公司采用网下向符合条 件的投资者询价配售及网上向持有深圳市场非限售A股股份和非限售存托凭证市值的社会公众投资者定 价发行相结合的方式，向社会公众公开发行人民币普通股（A股）股票4,304.35万股，发行价为每股人 民 ...